Hyper or hypo fractionated dose escalation/acceleration using optimized cutting-edge technologies, including but not limited to image-guided radiotherapy, 3-D conformal radiotherapy, stereotactic ablative radiotherapy (SABR), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT) and proton therapy, will likely lead to improved clinical outcomes, but further studies are needed. Personalized approaches based on functional images, tumor genetic make-up to guide the use of systemic therapy for selected patients, and personalized radiotherapy to maximize local control with dose escalation/acceleration while minimizing toxicity, are all crucial for improving the therapeutic ratio in NSCLC. To present a comprehensive review in the up-to date application of radiation escalation, Drs Joe Y. Chang (MD Anderson Cancer Center, USA) and Dirk De Ruysscher (University Hospitals Leuven/ KU Leuven, Belgium) are guest-editing a special issue on Hypo- and hyper-fractionated radiotherapy in non-small cell lung cancer using cutting-edge technologies, which will reflect a collaborative effort from multiple international contributors.
This special will provide state of the art review of biology, rationales, techniques and clinical outcome of novel radiotherapy regiments of hypo- and hyper-fractionated radiotherapy in non-small cell lung cancer using cutting-edge technologies and combining molecular target therapy and will be available by the end of 2013.
Topics to be covered in this special issue are as follows:
Editorial
Joe Y. Chang/ USA, Dirk De Ruysscher/ Belgium
Hypo- and hyper- fractionated radiotherapy: “new biology” or just dose escalation
Mansoor M Ahmed / USA
Hyperfractionated and accelerated radiotherapy in NSCLC
Christophe Pöttgen/ Germany, Corinne Faivre-Finn/ UK
Accelerated dose escalation with proton beam therapy for non-small cell lung cancer
Daniel Gomez, Joe Y. Chang / USA
Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: Overview of current possibilities
Van Elmpt W/ Netherlands, Dirk De Ruysscher/ Belgium
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC
Sanjay Popat/ UK
Can dose escalation improve survival in stage III NSCLC
Fong-Ming (Spring) Kong /USA
Improving radiotherapy planning, delivery accuracy, and normal tissue sparing using cutting edge technologies
Carri K. Glide-Hurst, Indrin J. Chetty/ USA
Stereotactic ablative radiotherapy in stage III NSCLC
David A Palma/ Canada
Local Control Rates with Five-Fraction Stereotactic Body Radiotherapy for Oligometastatic Cancer to the Lung
Milano Michael/ USA
Molecular Markers to Predict Clinical Outcome and Radiation Induced Toxicity in Lung Cancer
Bo Lu / USA